Recent Interviews

Lewis Black, CEO, Almonty Industries

Lewis Black
CEO | Almonty Industries
100 King Street West, M5X 1C7 Toronto (CAN)

+1 (647) 438-9766

Interview with mine operator Almonty Industries: "Tungsten makes e-cars better"

Nick Luksha, President, Prospect Ridge Resources

Nick Luksha
President | Prospect Ridge Resources
1288 West Cordova Street Suite 2807, V6C 3R3 Vancouver (CAN)

Interview Prospect Ridge Resources: These fillets taste good to the market

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)


Interview Clean Logistics: Hydrogen challenge to Daimler + Co.

02. November 2020 | 09:07 CET

Ballard Power, Saturn Oil & Gas, Amazon - The profiteers of the crisis!

  • Covid-19
Photo credits:

The profiteers of the first wave of the Corona pandemic are seen from the most recently published quarterly figures. The well-known FAANG stocks Facebook, Amazon, Apple, Netflix and Alphabet (Google) were able to improve their balance sheets significantly. Besides some winners, the number of losers is much larger. These now either have to fight for survival or are swallowed cheaply by financially more robust competitors. The takeover wave should pick up speed in 2021, across all industries!

time to read: 2 minutes by Stefan Feulner
ISIN: CA80412L1076 , CA0585861085 , US0231351067



Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author

The pike in the carp pond

Due to the sharp drop in prices, there are also great opportunities in the oil market to grow disproportionately through acquisitions. The prerequisite is that you are blessed with cash and have already localized the possible takeover targets. For John Jeffrey, the experienced CEO and Chairman of Saturn Oil & Gas, the current circumstances are just perfect. For Jeffrey, it is clear that buying in competitors offers clear advantages over its own drilling program. The current market capitalization of the Canadians is currently at favorable EUR 15 million. Targeted acquisitions would take the Company into new dimensions.

Strategically sensible

Understandably, Jeffrey is keen not to produce at a much higher cost in the future than at present. In 2019, Saturn Oil & Gas was by far the cheapest oil producer in Canada. At only around USD 12 per barrel of oil, the production costs were significantly lower than those of the large, well-known oil producers, which had production costs of well over USD 30 per barrel.

Change in management indicates growth

Only yesterday, the news came in that Saturn Oil & Gas will continue to strengthen its position. Wendy Woolsey is joining the team headed by Jeffrey on an interim basis. Woolsey herself has more than 25 years of experience in the Canadian oil and gas industry. She served as Vice President, Finance and Chief Financial Officer of Yoho Resources Inc. from 2005 to 2016 and before that as Manager of Finance at Baytex Energy and Vice President, Finance and Chief Financial Officer of Symmetry Resources Inc. For Jeffrey, this is another coup and possibly a sign of further growth for Saturn Oil & Gas Inc. We can be excited about what will follow in the coming weeks.

Strong partnership

Good news at Ballard Power. The Canadians have reached a final agreement with the automotive giant Audi on the extended use of the FCgen HPS fuel cell stack. According to the press release, the marketing of the new fuel cell development can start worldwide and across all industries, including trucks and passenger cars. Previously, Ballard had only the right to use the stack for a limited number of applications, including bus, rail, marine, mining, construction, aviation and stationary power applications.

Caution advised

Despite the very positive news, caution is advised at one of the leading fuel manufacturers. After the ongoing strong correction, the resistance zone, which was successfully defended last week, has to hold at around CAD 16.50. If not, the next way would be the 200-day line, which currently runs at approx. CAD 13.50.


One could guess that the figures for the third quarter would be positive. However, these even beat all analysts' estimates by a wide margin. Amazon increased its sales in the reporting period by 37% to USD 96.1 billion. Operating income rose to USD 6.2 billion, compared to USD 3.2 billion in the same period of the previous year. Earnings per share exploded to USD 12.37. Analysts had "only" expected proceeds of USD 93 billion, but they were clearly off target for earnings per share. They estimated this at only USD 7.41. With the recent lockdowns in almost all of Europe, nothing should stand in the way of an absolute record year.


Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

04. February 2021 | 08:15 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Johnson & Johnson: biotech gems from the well-known to the unknown

  • Covid-19

If there's one industry that's rightfully making big profits these days, it's healthcare companies. The pandemic has kissed the industry awake. In addition to the current relevance around Covid treatment, test procedures, or even vaccinations, there is also a growing awareness that medical innovation depends on research. More and more investors are willing to push promising projects and the general conditions for this could not be better. There is a consensus in politics, society and business that health is the highest good.


21. December 2020 | 07:50 CET | by Stefan Feulner

CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!

  • Covid-19

The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.


21. October 2020 | 12:42 CET | by Stefan Feulner

BioNTech, Valeo Pharma, Pfizer - Starting signal!

  • Covid-19

Who will make the race for the first approved Corona vaccine? Russia, China, and several North American suppliers are fighting for a place in the sun. The second and third parties should also benefit from the approval, as the demand is enormous among the nearly 8 billion inhabitants of the earth. One thing is clear; the winners of this almost macabre-sounding "Corona contest" will go through the roof. Those who receive late approval or no approval at all risk extinction. Admittedly, the world is looking at the long-awaited miracle cure. But there are easier ways for every individual to protect themselves against viruses.